Nikhil Khushalani, MD

Associate Professor of Oncology

Section Chief, Soft Tissue and Melanoma

Director, IL-2 Program

Roswell Park Cancer Institute

Profile

Areas of Expertise:

Melanoma

Sarcoma

Gastrointestinal stromal tumors (GIST)

Biological therapy in cancer

Research

Research Interests:

Investigation of novel therapeutics, including anti-angiogenics in melanoma and sarcoma

Investigate immunotherapy approaches for melanoma

Identify predictors of response to high-dose Interleukin-2 biotherapy

Background Information

Education and Training:

MD - Topiwala National Medical College, University of Mumbai, Maharashtra, India

Residency:

School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Board Certification:

Internal Medicine, American Board of Internal Medicine

Medical Oncology, American Board of Internal Medicine

Fellowships:

Roswell Park Cancer Institute, Buffalo, NY

Publications

Publications:

May KS, Javle MM, Gibbs JF, Kuvshinoff BW, Fakih M, Russo RC, Flaherty L, Ma WW, Iyer RV, Wilding GE, Chandrasekhar R, Khushalani NI, Yang GY. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. International journal of radiation oncology, biology, physics 2010; 76(4):1193-1198
Yang GY, Fakih M, Gibbs JF, Yendamuri SS, Khushalani NI, McCloskey SA, Wilding GE, Chandrasekhar R, Iyer RV, May KS, Thomas Jr CR. Renal atrophy secondary to chemoradiotherapy of abdominal malignancies. International journal of radiation oncology, biology, physics 2010; 78(2):539-546
Lee RY , Flaherty L , Khushalani NI , Kanehira K , Nwogu C , Yendamuri S , Nava HR , Yang GY. Aorto-esophageal fistula: a rare fatal case caused by esophageal malignancy. Journal of gastrointestinal oncology 2010; 1(1):64-67
May KS , Lamonica D , Nava HR , Gibbs JF , Yendamuri SS , Nwogu CE , Iyer RV , Yap JC , Warner JC , Russo RC , Malhotra HK , Flaherty L , Wilding GE , Chandrasekhar R , Khushalani NI , Yang GY , Thomas Jr CR. Association of Technetium(99m) MAG-3 renal scintigraphy with change in creatinine clearance following chemoradiation to the abdomen in patients with gastrointestinal malignancies. Journal of gastrointestinal oncology 2010; 1(1):7-15
Yendamuri S , Gutierrez L , Oni A , Mashtare T , Khushalani N, Yang G , Nava H , Demmy T , Nwogu C. Does circular stapled esophagogastric anastomotic size affect the incidence of postoperative strictures?. Journal of surgical research 2011; 165(1):1-4
Khushalani NI, Fetterly GJ, Iyer RV, Litwin A, Brady W, Javle MM. Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers. Journal of clinical oncology 2010; 28(15 Suppl.):TPS201
Khushalani NI, Nava HR, Nwogu CE, Yendamuri SS, Iyer RV, Wang D, Miecznikowski J, Tan W, Yang G, Javle MM. Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC). Journal of clinical oncology 2010; 28(15 Suppl.):4100
Iyer RV, Fakih M, Ma W, Tucker C, Levea C, Starostik P, Litwin A, Tan W, Khushalani NI, Adjei AA. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract# 258
Puthillath A, Mashtare Jr T, Wilding G, Khushalani N, Steinbrenner L, Ross ME, Romano K, Wisniewski M, Fakih MG. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Critical reviews in oncology/hematology 2009; 71(3):242-248
Iyer R, Javle M, Robins M, Levea C, Litwin A, Nava H, Tan W, Shefter T, Yang G, Khushalani NI. Phase II multicenter study of erlotinib and radiation therapy (RT) for elderly patients (PTS) with esophageal carcinoma (EC)- final report. Annals of oncology 2010; 21(Suppl. 8):259-260
Khushalani NI, Brady W, Fetterly G, Prey J, Levea C, Litwin A, Grande C, Iyer R, Javle M. Continuous and intermittent vorinostat (V) in combination with folfiri in advanced upper gastrointestinal cancer (AUGC): Preliminary results of a phase I pharmacokinetic (PK) study. Annals of oncology 2010; 21(Suppl. 8):260
May KS, Yang GY, Khushalani NI. The role of radiation in the perioperative treatment of esophagogastric cancer. Current treatment options in oncology 2011; 12(1):61-71
Ettinger DS, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Javle M, Jacobs CD, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Zhen W. Occult primary. Journal of the National Comprehensive Cancer Network : JNCCN 2008; 6(10):1026-1060
Khushalani N. Cancer of the esophagus and stomach. Mayo Clinic proceedings 2008; 83(6):712-722
Ramnath N, Yu J, Khushalani NI, Gottlieb RH, Schwarz JK, Iyer RV, Rustum YM, Creaven PJ. Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. Anti-cancer drugs 2008; 19(7):749-752
Malik NK, Warren GW, Yang G, Zeeck K, Papsidero T, Patil S, Khushalani NI, Sher T, Yendamuri SS, Nava HR, Salerno May K. Response-based outcomes in patients with esophageal cancer treated with primarily non-cisplatin and 5-fluorouracil-based trimodality therapy : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):e14620
Salerno May K, Malik NK, Yang G, Patil S, Flaherty L, Khushalani NI, Sher T, Yendamuri SS, Nava HR, Warren GW. The effect of smoking history on response and survival outcomes patients with in esophageal cancer treated with neoadjuvant concurrent chemoradiotherapy followed by surgery : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):e14601
Iyer RV, Yang G, Schefter TE, Tan W, Nava HR, Levea C, Litwin A, Robins M, Khushalani NI. Phase II multicenter study of erlotinib with radiation therapy (RT) for elderly patients (pts) with esophageal carcinoma (EC): Final report : 2011 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2011; 29(4 Suppl.):135
Bharthuar A, Khoury T, Haas KN, Mashtare T, Black J, Baer M, Yang G, Khushalani N, Iyer RV. Expression of breast cancer resistance protein (BCRP) in esophageal cancers (EC). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e13529
Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI. A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15540
Iyer R, Khushalani N, Tan W, Litwin A, LeVea C, Hutson A, Tucker C, Ma W, Fakih M, Adjei A. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G). European journal of cancer (Oxford, England : 1990) 2009; 7(2):391
Iyer R, Rossi M, Javle M, Lo K, Cowell J, Khushalani N, Kuvshinoff B, Gibbs J. Evaluation of phosphatidyl inositol 3-kinase catalytic subunit (PI3KCA) and epidermal growth factor receptor (EGFR) gene mutations in pancreatic adenocarcinoma. Annals of surgical oncology 2008; 15(Suppl. 2):33
Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME, Tan W, Iyer R, Yang G, Pendyala L. Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15543
May KS, Fakih M, Khushalani N, Chandrasekhar R, Wilding G, Park L, Flaherty L, Russo R, Iyer R, Yang G. Renal Function following Abdominal Chemoradiotherapy for Gastrointestinal Malignancies in Elderly Patients. International journal of radiation oncology, biology, physics 2009; 75(3 Suppl.):S268-S269
May KSS, Yang GY, Iyer RV, Chandrasekhar R, Wilding G, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M. Renal atrophy secondary to chemoradiation treatment of abdominal malignancies. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15532
Sharma R, Yang GY, Nava HR, Demmy TL, Nwogu CE, Yendamuri SS, Lamonica D, Tan W, Iyer RV, Khushalani NI. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15619
Yang G, Khushalani NI, Chandrasekhar R, Wilding GE, McCloskey SA, Flaherty L, Yap JC, Gibbs JF, Fakih MG, May KS. Renal Atrophy Secondary to Abdominal Chemoradiotherapy: Receiver Operating Characteristic (ROC) Analysis. International journal of radiation oncology, biology, physics 2009; 75(3 Suppl.):S262-S263
Yang GY, Flaherty L, Wagner TD, Yap JC, Chandrasekhar R, Wilding G, Khushalani NI, Iyer RV, Lamonica D, Thomas CR. Subclinical impairment of renal function following abdominal radiotherapy: An analysis using specific scintigraphic and biochemical endpoints. International journal of radiation oncology, biology, physics 2008; 72(1 Suppl.):S478-S479
Yap JC, Yang GY, Fakih M, Mashtare T, Dunn KB, Kuvshinoff BW, Smith J, Khushalani NI, Gibbs JF. Primary adenocarcinoma of the anus: a 22-year SEER population database analysis. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15072
Wagner TD, Khushalani N, Yang GY. Clinical T2N0M0 carcinoma of thoracic esophagus. Journal of thoracic disease 2010; 2(1):36-42
Jarkowski A 3rd, Hare R, Francescutti V, Wilkinson N, Khushalani N. Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor. Anticancer research 2011; 31(10):3429-3432
Khushalani NI. Phase I and II clinical trials for gastric cancer. Surgical oncology clinics of North America 2012; 21(1):113-128
Iyer R, Fetterly G, Groman A, Hutson A, Khushalani N, Mohile S, Ashton E, Litwin A, Grande C, Tomaszewski G. Sunitinib and Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma (HCC)- Final Results of a Phase 2 Trial. European journal of cancer (Oxford, England : 1990) 2011; 47(Suppl. 1):S447
Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson III WE, Daud A, Dilawari RA, DiMaio D, Guild V, Halpern AC, Hodi Jr FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(3):366-400
Damodaran S, Bellavia T, Sait SNJ, Wang ES, Wetzler M, Khushalani NI. Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. Clinical colorectal cancer 2012; 11(2):151-154
Dhillon SS, Berim IG, Khushalani N, Gannon J. Detection of a possible case of pulmonary tumour thromboembolism by endobronchial ultrasound. Monaldi archives for chest disease 2012; 77(1):40-42
Nurkin S, Nava HR, Yendamuri S, Levea CM, Nwogu C, Wilding G, Khushalani N. Outcomes of Endoscopic Resection for High Grade Dysplasia and Esophageal Cancer. Gastrointestinal endoscopy 2012; 75(4 Suppl.):473
Iyer RV, Tomaszewski G, Wu YV, Kuvshinoff BW, Groman AE, Khushalani NI, Grande C, Zagst PD, Clark K, Fetterly GJ. Advanced hepatocellular carcinoma (HCC) treated with sunitinib (Su) and transarterial chemoembolization (TACE): Phase II trial final report : 2012 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2012; 30(4 Suppl.):Abstract #275
Jarkowski A, Hare RB, Loud P, Skitzki JJ, Kane JM, Salerno MK, Zeitouni N, Nestico J, Vona KL, Groman AE, Khushalani NI. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): The Roswell Park experience : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e19041
Dawar R, Khushalani N, Fabiano A, Qiu JX. A Rare Case of Secondary Gliosarcoma with Extracranial Metastases. Journal of neuropathology and experimental neurology 2012; 71(6):567-568 (Abstract #75)

Referral

Email:

Nikhil.Khushalani@RoswellPark.org

Fax:

716-845-8935